Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose.
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose.
复制标题
DOI：
10.1126/science.abh1282
复制
发表时间：
2021-04-30
期刊：
影响因子：
--
通讯作者：
Boyton R
中科院分区：
文献类型：
--
作者：
Reynolds CJ;Pade C;Gibbons JM;Butler DK;Otter AD;Menacho K;Fontana M;Smit A;Sackville-West JE;Cutino-Moguel T;Maini MK;Chain B;Noursadeghi M;UK COVIDsortium Immune Correlates Network;Brooks T;Semper A;Manisty C;Treibel TA;Moon JC;UK COVIDsortium Investigators;Valdes AM;McKnight Á;Altmann DM;Boyton R
在严重急性呼吸综合征冠状病毒2型疫苗的临床试验期间，没有对感染该病毒的幸存者进行检测。在宣布大流行病一年后，为以前感染的人接种疫苗成为现实。Reynolds等人讨论了一组接受辉瑞/BioNTech疫苗的英国卫生保健工作者的知识差距，其中一半参与者在大流行早期经历了自然病毒感染（见Crotty的观点）。基因分型表明，一个遗传成分的基础异质性免疫反应疫苗和自然感染。接种疫苗后，未感染的个体产生了与自然感染者相似的抗体反应，但T细胞反应更有限，有时甚至不存在。然而，在感染后接种疫苗的个体中的抗体和记忆应答大幅增强，以至于单次疫苗剂量可能保护免受更具侵略性的B.1.1.7变体的侵害。信使RNA疫苗可能具有佐剂作用，使反应偏向抗体产生。Science，abh 1282，本期第1418页;也可参见abj 2258，第1418页。先前的感染导致对单一BNT 162 b2疫苗剂量的增强的变异交叉保护性T和B细胞应答。严重急性呼吸系统综合征冠状病毒2型（SARS-CoV-2）疫苗的推出恰逢令人担忧的变异株的传播。我们研究了单次接种疫苗（有或没有既往感染）是否对变异体产生交叉保护性免疫。我们分析了医务工作者（HCW）首次接种Pfizer/BioNTech信使RNA疫苗BNT 162 b2后的T和B细胞应答，随后进行纵向随访，既往有或无武汉-Hu-1 SARS-CoV-2感染。一剂后，既往感染过的个体表现出增强的T细胞免疫力、对刺突蛋白的抗体分泌记忆B细胞反应以及有效对抗变体B.1.1.7和B.1.351的中和抗体。相比之下，接受一剂疫苗而先前没有感染的HCW显示出对变体的免疫力降低。B.1.1.7和B.1.351刺突突变导致T细胞应答增加、消除或不变，这取决于人类白细胞抗原（HLA）多态性。在先前感染异源变体的情况下用BNT 162 b2进行单剂量疫苗接种显著增强了针对变体的中和抗体应答。
During clinical trials of severe acute respiratory syndrome coronavirus 2 vaccines, no one who had survived infection with the virus was tested. A year after the pandemic was declared, vaccination of previously infected persons is a reality. Reynolds et al. address the knowledge gap in a cohort of UK health care workers given the Pfizer/BioNTech vaccine in which half of the participants had experienced natural virus infections early in the pandemic (see the Perspective by Crotty). Genotyping indicated that a genetic component underlies heterogeneity in immune responses to vaccine and to natural infection. After vaccination, naïve individuals developed antibody responses similar to those seen in naturally infected persons, but T cell responses were more limited and sometimes absent. However, antibody and memory responses in individuals vaccinated after infection were substantially boosted to the extent that a single vaccine dose is likely to protect against the more aggressive B.1.1.7 variant. It is possible that the messenger RNA vaccine has an adjuvant effect, biasing responses toward antibody generation. Science, abh1282, this issue p. 1418; see also abj2258, p. Previous infection results in enhanced variant cross-protective T and B cell responses to a single BNT162b2 vaccine dose. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has coincided with the spread of variants of concern. We investigated whether single-dose vaccination, with or without prior infection, confers cross-protective immunity to variants. We analyzed T and B cell responses after first-dose vaccination with the Pfizer/BioNTech messenger RNA vaccine BNT162b2 in health care workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody-secreting memory B cell response to the spike protein, and neutralizing antibodies effective against variants B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated, or unchanged T cell responses, depending on human leukocyte antigen (HLA) polymorphisms. Single-dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.4049/jimmunol.1402862
发表时间：
2015-05-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Reynolds C;Goudet A;Jenjaroen K;Sumonwiriya M;Rinchai D;Musson J;Overbeek S;Makinde J;Quigley K;Manji J;Spink N;Yos P;Wuthiekanun V;Bancroft G;Robinson J;Lertmemongkolchai G;Dunachie S;Maillere B;Holden M;Altmann D;Boyton R
通讯作者：
Boyton R
影响因子：
24.8
作者：
Goel RR;Apostolidis SA;Painter MM;Mathew D;Pattekar A;Kuthuru O;Gouma S;Hicks P;Meng W;Rosenfeld AM;Dysinger S;Lundgreen KA;Kuri-Cervantes L;Adamski S;Hicks A;Korte S;Oldridge DA;Baxter AE;Giles JR;Weirick ME;McAllister CM;Dougherty J;Long S;D'Andrea K;Hamilton JT;Betts MR;Luning Prak ET;Bates P;Hensley SE;Greenplate AR;Wherry EJ
通讯作者：
Wherry EJ
影响因子：
64.8
作者：
Wang, Zijun;Schmidt, Fabian;Nussenzweig, Michel C.
通讯作者：
Nussenzweig, Michel C.
影响因子：
24.8
作者：
Reynolds CJ;Swadling L;Gibbons JM;Pade C;Jensen MP;Diniz MO;Schmidt NM;Butler DK;Amin OE;Bailey SNL;Murray SM;Pieper FP;Taylor S;Jones J;Jones M;Lee WJ;Rosenheim J;Chandran A;Joy G;Di Genova C;Temperton N;Lambourne J;Cutino-Moguel T;Andiapen M;Fontana M;Smit A;Semper A;O'Brien B;Chain B;Brooks T;Manisty C;Treibel T;Moon JC;COVIDsortium investigators;Noursadeghi M;COVIDsortium immune correlates network;Altmann DM;Maini MK;McKnight Á;Boyton RJ
通讯作者：
Boyton RJ